Alembic Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The inspection was conducted from 9th February to 18th February 2026. At the end of the inspection, a ?Form 483? was issued with 2 observations and the company said that it will respond to the US FDA within the stipulated timelines.

Alembic Pharmaceuticals, a vertically integrated research and development company, is engaged in the manufacture and marketing of generic pharmaceutical products across global markets.

The company?s consolidated net profit fell 3.9% to Rs 132.97 crore despite a 10.8% jump in net sales to Rs 1,876.31 crore in Q3 FY26 over Q3 FY25.

Powered by Capital Market - Live News

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Stalevo Tablets, manufactured by Orion Corporation. These tablets are indicated for the treatment of Parkinson?s disease.

With this approval, Alembic Pharmaceuticals now has a cumulative total of 234 ANDA approvals from the USFDA, including 214 final approvals and 20 tentative approvals.

Alembic Pharmaceuticals, a vertically integrated research and development company, is engaged in the manufacture and marketing of generic pharmaceutical products across global markets.

On the financial front, the company reported a consolidated net profit of Rs 184.71 crore in Q2 FY26, up 20.40% from Rs 153.41 crore in Q2 FY25. Revenue from operations rose 15.90% year-on-year to Rs 1,910.15 crore in the quarter ended September 2025.

Shares of Alembic Pharmaceuticals declined 2.17% to Rs 792.15 on the BSE.

Powered by Capital Market - Live News

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbidopa, Levodopa and Entacapone Tablets, 12.5 mg/50 mg/200 mg, 18.75 mg/75 mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg, and 50 mg/200 mg/200 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets, 12.5 mg/50 mg/200 mg, 18.75 mg/75 mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg, and 50 mg/200 mg/200 mg, of Orion Corporation.

Carbidopa, levodopa and entacapone tablets are indicated for the treatment of Parkinson's disease.

Powered by Capital Market - Live News

Net profit of Alembic Pharmaceuticals declined 3.94% to Rs 132.97 crore in the quarter ended December 2025 as against Rs 138.42 crore during the previous quarter ended December 2024. Sales rose 10.84% to Rs 1876.31 crore in the quarter ended December 2025 as against Rs 1692.74 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News